1. Trang chủ
  2. » Y Tế - Sức Khỏe

Tài liệu CLINICAL PHARMACOLOGY 2003 (PART 10) pdf

16 354 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Tiêu đề Unwanted effects and adverse drug reactions
Chuyên ngành Clinical Pharmacology
Thể loại Chapter
Năm xuất bản 2003
Định dạng
Số trang 16
Dung lượng 1,98 MB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Unwanted effects and adverse drug reactions SYNOPSIS Background Definitions Causation: degrees of certainty Pharmacovigilance and pharmacoepidemiology Classification Causes Allergy in re

Trang 1

Unwanted effects and adverse drug reactions

SYNOPSIS

Background

Definitions

Causation: degrees of certainty

Pharmacovigilance and

pharmacoepidemiology

Classification

Causes

Allergy in response to drugs

Effects of prolonged administration: chronic

organ toxicity

Adverse effects on reproduction

Background

Cur'd yesterday of my disease

I died last night of my physician.1

Nature is neutral, i.e it has no 'intentions' towards

humans, though it is often unfavourable to them It is

mankind, in its desire to avoid suffering and death,

that decides that some of the biological effects of

drugs are desirable (therapeutic) and others are

undesirable (adverse) In addition to this arbitrary

division, which has no fundamental biological basis,

1 From, The remedy worse than the disease Matthew Prior

(1664-1721).

unwanted effects of drugs are promoted, or even caused, by numerous nondrug factors Because of the variety of these factors, attempts to make a simple account of the unwanted effects of drugs must be imperfect

There is general agreement that drugs prescribed for disease are themselves the cause of a serious amount of disease (adverse reactions), ranging from mere inconvenience to permanent disability and death

Since drugs are intended to relieve suffering, patients find it peculiarly offensive that they can also cause disease (especially if they are not forewarned) Therefore it is important to know how much dis-ease they do cause and why they cause it, so that preventive measures can be taken

It is not enough to measure the incidence of adverse reactions to drugs, their nature and their severity, though accurate data are obviously useful

It is necessary to take, or to try to take, into acc-ount which effects are avoidable (by skilled choice and use) and which are unavoidable (inherent

in drug or patient) Also, different adverse effects can matter to a different degree to different people

Since there can be no hope of eliminating all adverse effects of drugs it is necessary to evaluate patterns of adverse reaction against each other One drug may frequently cause minor ill-effects but pose no threat to life, though patients do not like it and may take it irregularly, to their own detriment Another drug may be pleasant to take, so that patients take it consistently, with benefit, but it may

Trang 2

rarely kill someone It is not obvious which drug is

to be preferred

Some patients, e.g those with a history of allergy

or previous reactions to drugs, are up to four times

more likely to have another adverse reaction, so

that the incidence does not fall evenly It is also

useful to discover the causes of adverse reactions,

for such knowledge can be used to render

avoid-able what are at present unavoidavoid-able reactions

Avoidable adverse effects will be reduced by

more skilful prescribing and this means that

doctors, amongst all the other claims on their

time, must find time better to understand drugs,

as well as to understand their patients and their

diseases

Definitions

Many unwanted effects of drugs are medically

trivial, and in order to avoid inflating the figures

of drug-induced disease, it is convenient to retain

the term side-effects for minor effects of type A

events/effects (p 139)

The term adverse reaction should be confined

to: harmful or seriously unpleasant effects

occurr-ing at doses intended for therapeutic (includoccurr-ing

prophylactic or diagnostic) effect and which call

for reduction of dose or withdrawal of the drug

and/or forecast hazard from future administration;

it is effects of this order that are of importance in

evaluating drug-induced disease in the community

Toxicity implies a direct action of the drug, often at

high dose, damaging cells, e.g liver damage from

paracetamol overdose, eighth cranial nerve damage

from gentamicin All drugs, for practical purposes,

are toxic in overdose and overdose can be absolute

or relative; in the latter case an ordinary dose may

be administered but may be toxic due to an

under-lying abnormality in the patient, e.g disease of the

kidney Mutagenicity, carcinogenicity and

terato-genicity (see index) are special cases of toxicity

Secondary effects are the indirect consequences

of a primary drug action Examples are: vitamin

deficiency or opportunistic infection which may

occur in patients whose normal bowel flora has been

altered by antibiotics; diuretic-induced hypokalaemia causing digoxin intolerance

Intolerance means a low threshold to the normal pharmacodynamic action of a drug Individuals vary greatly in their susceptibility to drugs, those at one extreme of the normal distribution curve being intolerant of the drugs, those at the other, tolerant Idiosyncrasy (see Pharmacogenetics) implies an inherent qualitative abnormal reaction to a drug, usually due to genetic abnormality, e.g porphyria

Causation: degrees of conviction

Reliable attribution of a cause-effect relationship provides the biggest problem in this field The following degrees of conviction assist in attributing adverse events to drugs:2

• Definite: time sequence from taking the drug is

reasonable; event corresponds to what is known

of the drug; event ceases on stopping the drug; event returns on restarting the drug (rarely advisable)

• Probable: time sequence is reasonable; event

corresponds to what is known of the drug; event ceases on stopping the drug; event not

reasonably explained by patient's disease

• Possible: time sequence is reasonable; event

corresponds to what is known of the drug; event could readily have been result of the patient's disease or other therapy

• Conditional: time sequence is reasonable; event

does not correspond to what is known of the drug; event could not reasonably be explained

by the patient's disease

• Doubtful: event not meeting the above criteria.

Recognition of adverse drug reactions When an unexpected event, for which there is no obvious cause, occurs in a patient already taking a drug, the possibility that it is drug-caused must always

Journal of the American Medical Association 1975 234: 1236.

Trang 3

PH ARM A C O V I G I L A N C E AND P H A R M A C O E P I D E M I O L O G Y 8

be considered Distinguishing between natural

pro-gression of a disease and drug-induced

deteriora-tion is particularly challenging, e.g sodium in

antacid formulations may aggravate cardiac failure,

tricyclic antidepressants may provoke epileptic

seizures, bronchospasm may be caused by aspirin

in some asthmatics

Pharmacovigilance and

pharmacoepidemiology

The principal methods of collecting data on adverse

reactions (pharmacovigilance) are:

• Experimental studies, i.e formal therapeutic trials

of Phases 1-3 These provide reliable data on

only the commoner events as they involve

relatively small numbers of patients (hundreds);

they detect an incidence of up to about 1:200

• Observational studies, where the drug is observed

epidemiologically under conditions of normal

use in the community, i.e

pharmaco-epidemiology Techniques used for

post-marketing (Phase 4) studies include the

obser-vational cohort study and the case-control study

The systems are described on page 69

DRUG-INDUCED ILLNESS

The discovery of drug-induced illness can be

analysed thus:3

• Drug commonly induces an otherwise rare

illness: this effect is likely to be discovered by

clinical observation in the licensing

(premarketing) formal therapeutic trials and the

drug will almost always be abandoned; but some

patients are normally excluded from such trials,

e.g pregnant women, and detection will then

occur later

• Drug rarely induces an otherwise common

illness: this effect is likely to remain

undiscovered

• Drug rarely induces an otherwise rare illness:

3 After: Jick H 1977 New England Journal of Medicine 296:

481-485.

this effect is likely to remain undiscovered before the drug is released for general prescribing; the effect should be detected by informal clinical observation or during any special

postregistration surveillance and confirmed by a case-control study (see p 68), e.g chloram-phenicol and aplastic anaemia; practolol and oculomucocutaneous syndrome

• Drug commonly induces an otherwise common illness: this effect will not be discovered by informal clinical observation If very common, it may be discovered in formal therapeutic trials and in case-control studies, but if only moderately common it may require observational cohort studies, e.g proarrhythmic effects of antiarrhythmic drugs

• Drug adverse effects and illness incidence in intermediate range: both case-control and cohort studies may be needed

Some impression of the features of drug-induced illness can be gained from the following statistics:

• Adverse reactions cause 2-3% of consultations in general practice

• Adverse reactions account for 5% of all hospital admissions

• Overall incidence in hospital inpatients is 10-20%, with possible prolongation of hospital stay in 2-10% of patients in acute medical wards

• A review of records of a Coroner's Inquests for a district with a population of 1.19 million (UK) during the period 1986-91 found that of 3277 inquests on deaths, 10 were due to errors of prescribing and 36 were caused by adverse drug reactions.4 Nevertheless, 17 doctors in the UK were charged with manslaughter in the 1990s compared with two in each of the preceding decades, a reflection of 'a greater readiness to call the police or to prosecute'.5

• Predisposing factors: age over 60 years or under one month, female, previous history of adverse reaction, hepatic or renal disease

4 Ferner R E, Whittington R M 1994 Journal of the Royal Society of Medicine 87:145-148.

5 Ferner R E 2000 Medication errors that have led to manslaughter charges British Medical Journal 321:

1212-1216.

Trang 4

• Adverse reactions most commonly occur early in

therapy (days 1-10)

It is important to avoid alarmist or defeatist

extremes of attitude Many treatments are dangerous,

e.g surgery, electroshock, drugs, and it is irrational

to accept the risks of surgery for biliary stones

or hernia and refuse to accept any risk at all from

drugs for conditions of comparable seriousness

Many patients whose death is deemed to be

partly or wholly caused by drugs are dangerously

ill already; justified risks may be taken in the hope

of helping them; ill-informed criticism in such cases

can act against the interest of the sick On the other

hand there is no doubt that some of these accidents

are avoidable Avoidability is often more obvious

when reviewing the conduct of treatment after death,

i.e with hindsight, than it was at the time

Sir Anthony Carlisle,6 in the first half of the 19th

century, said that 'medicine is an art founded on

conjecture and improved by murder' Although

medicine has advanced rapidly, there is still a ring

of truth in that statement to anyone who follows the

introduction of new drugs and observes how, after

the early enthusiasm, the reports of serious toxic

effects appear The challenge is to find and avoid

these, and indeed, the present systems for detecting

adverse reactions came into being largely in the wake

of the thalidomide, practolol and benoxaprofen

disasters (see Ch 5); they are now an increasingly

sophisticated and effective part of medicines

development

Another cryptic remark of this therapeutic

nihilist was 'digitalis kills people' and this is true

William Withering in 1785 laid down rules for the

use of digitalis that would serve today Neglect

of these rules resulted in needless suffering for

patients with heart failure for more than a century

until the therapeutic criteria were rediscovered

Any drug that is really worth using can do harm

It is an absolute obligation on doctors to use only drugs

about which they have troubled to inform themselves.

Effective therapy depends not only on the

correct choice of drugs but also on their correct use

6 Noted for his advocacy of the use of 'the simple carpenter's

saw' in surgery.

This latter is sometimes forgotten and a drug is condemned as useless when it has been used in

a dose or way which absolutely precluded a successful result; this can be regarded as a negative adverse effect

PRACTICALITIES OF DETECTING RARE ADVERSE REACTIONS

For reactions with no background incidence the number of patients required to give a good (95%) chance of detecting the effect is given in Table 8.1 Assuming that three events are required before any regulatory or other action should be taken, it shows the large number of patients that must be monitored to detect even a relatively high incidence adverse effect The problem can be many orders of magnitude worse if the adverse reactions closely resemble spontaneous disease with a background incidence in the population

Caution About 80% of well people not taking any drugs admit on questioning to symptoms (often several) such as are commonly experienced as lesser adverse reactions to drugs These symptoms are intensified (or diminished) by administration of

a placebo Thus, many (minor) symptoms may be wrongly attributed to drugs

Classification

It is convenient to classify adverse reactions to drugs under the following headings:

TABLE 8.1 Detecting rare adverse reactions7

Expected incidence Required number of

of adverse reaction patients for event

I event 2 events 3 events

I in 100 300 480 650

I in 200 600 960 1300

I in 1000 3000 4800 6500

I in 2000 6000 9600 13 000

I in 10000 30000 48000 65000

7 By permission from, Safety requirements for the first use of new drugs and diagnostic agents in man CIOMS (WHO)

1983 Geneva.

Trang 5

C A U S E S 8

Type A (Augmented) reactions will occur in

everyone if enough of the drug is given because

they are due to excess of normal, predictable,

dose-related, pharmacodynamic effects They are

common and skilled management reduces their

incidence, e.g postural hypotension, hypoglycaemia,

hypokalaemia

Type B (Bizarre) reactions will occur only in

some people They are not part of the normal

pharmacology of the drug, are not dose-related and

are due to unusual attributes of the patient

interact-ing with the drug These effects are predictable

where the mechanism is known (though predictive

tests may be expensive or impracticable), otherwise

they are unpredictable for the individual, although

the incidence may be known The class includes

unwanted effects due to inherited abnormalities

(idiosyncrasy) (see Pharmacogenetics) and

immuno-logical processes (see Drug allergy) These account

for most drug fatalities

Type C (Chronic) reactions due to long-term

exposure, e.g analgesic nephropathy, dyskinesias

with levodopa

Type D (Delayed) effects following prolonged

exposure, e.g carcinogenesis or short-term exposure

at a critical time, e.g teratogenesis

Type E (Ending of use) reactions, where

dis-continuation of chronic therapy is too abrupt, e.g

of adrenal steroid causing rebound adrenocortical

insufficiency, of opioid causing the withdrawal

syndrome

Causes

When an unusual or unexpected event, for which

there is no evident natural explanation, occurs in a

patient already taking a drug, the possibility that

the event is drug-caused must always be

consi-dered, and may be categorised as follows:

• The patient may be predisposed by age, genetic

constitution, tendency to allergy, disease,

personality, habits

• The drug Anticancer agents are by their nature

cytotoxic Some drugs, e.g digoxin, have steep

dose-response curves and small increments of

dose are more likely to induce augmented (type

A) reactions Other drugs, e.g antimicrobials, have a tendency to cause allergy and may lead to bizarre (type B) reactions Ingredients of a formulation, e.g colouring, flavouring, sodium content, rather than the active drug may also cause adverse reactions

• The prescriber Adverse reactions may occur because a drug is used for an inappropriately long time (type C), at a critical phase in pregnancy (type D), is abruptly discontinued (type E) or given with other drugs (interactions) Aspects of the two sections above, Classification and Causes, appear throughout the book Selected topics are discussed below

AGE

The very old and the very young are liable to be intolerant of many drugs, largely because the mechanisms for disposing of them in the body are less efficient The young, it has been aptly said, are not simply 'small adults' and 'respect for their pharmacokinetic variability should be added to the list of our senior citizens' rights'.8 The old are also frequently exposed to multiple drug therapy which predisposes to adverse effects (see Prescribing for the elderly, p 126)

GENETIC CONSTITUTION

Inherited factors that influence response to drugs are discussed in general under Pharmacogenetics (p 122) It is convenient here to describe the porphyrias, a specific group of disorders for which careful prescribing is vital

The porphyrias comprise a number of rare, geneti-cally determined single enzyme defects in haem

biosynthesis Acute porphyrias (acute intermittent porphyria, variegate porphyria and hereditary coproporphyria) are characterised by severe attacks

of neurovisceral dysfunction precipitated principally by

a wide variety of drugs (and also by alcohol, fasting,

and infection); nonacute porphyrias (porphyria cutanea tarda, erythropoietic protoporphyria and congenital erythropoietic porphyria) present with cutaneous photosensitivity for which alcohol (and

8 Fogel B S 1983 New England Journal of Medicine 308:1600.

Trang 6

prescribed oestrogens in women) is the principle

provoking agent

In healthy people, forming haemoglobin for

their erythrocytes and haem-dependent enzymes,

the rate of haem synthesis is controlled by negative

feedback according to the amount of haem present

When more haem is needed there is increased

production of the rate-controlling enzyme

delta-aminolaevulinic acid (ALA) synthase which provides

the basis of the formation of porphyrin precursors of

haem But in people with porphyria one or other of

the enzymes that convert the various porphyrins

to haem is deficient and so porphyrins accumulate

A vicious cycle occurs: less haem —> more ALA

synthase —> more porphyrin precursors, the

meta-bolism of which is blocked, and a clinical attack

occurs

It is of interest that those who inherited acute

intermittent porphyria and variegate porphyria

suffered no biological disadvantage from the

natural environment and bred as well as the normal

population until the introduction of barbiturates

and sulphonamides They are now at serious

dis-advantage, for many other drugs can precipitate

fatal acute attacks

The exact precipitating mechanisms are uncertain

Increase in the haem-containing hepatic oxidising

enzymes of the cytochrome P450 group causes

an increased demand for haem Therefore drugs

that induce these enzymes would be expected to

precipitate acute attacks of porphyria and they do

so; tobacco smoking may act by this mechanism

Apparently unexplained attacks of porphyria should

be an indication for close enquiry into all possible

chemical intake Guaiphenesin, for example, is

hazardous; it is included in a multitude of

multi-ingredient cough medicines (often nonprescription)

Patients must be educated to understand their

condition, to possess a list of safe and unsafe drugs,

and to protect themselves from themselves and

from others, including prescribing doctors

The greatest care in prescribing for these patients

is required if serious illness is to be avoided

Patients (1 in 10 000 UK population) are so highly

vulnerable that lists of drugs known or believed to

be unsafe are available, e.g in the British National

Formulary Additionally, we provide a table of drugs

considered safe for use in the acute porphyrias at

the time of publication (Table 8.2) The list is revised

regularly, mostly with additions made as informa-tion becomes available Updated informainforma-tion can

be obtained.9

Use of a drug about which there is uncertainty may be justified Dr M Badminton writes: 'Essential treatment should never be withheld, especially for a condition that is serious or life-threatening The clinician should assess the severity of the condition and the activity of the porphyria If no recognised safe option is available, a reasonable course is to:

1 Measure urine porphyrin and porphobilinogen before starting treatment

2 Repeat the measurement at regular intervals or if the patient has symptoms in keeping with an acute attack If there is an increase in the precursor levels, stop the treatment and consider giving haem arginate for acute attack (see below)

3 Contact an expert centre for advice.'

In the treatment of the acute attack it is rational

to use any safe means of depressing the formation

of ALA-synthase Haem arginate (human haematin)

infusion, by replenishing haem and so removing the stimulus to ALA-synthase, is effective if given early, and may prevent chronic neuropathy Addi-tionally, attention to nutrition, particularly the supply

of carbohydrate, relief of pain (with an opioid), and

of hypertension and tachycardia (with a (B-adreno-ceptor blocker) are important Hyponatraemia is

a frequent complication, and plasma electrolytes should be monitored

In the treatment of the acute attack it would seem rational to use any safe means of depressing the

formation of ALA-synthase Indeed, haem arginate

(human haematin) infusion, by replenishing haem and so removing the stimulus to ALA-synthase, appears to be effective if given early, and may prevent chronic neuropathy Additionally, attention

to nutrition, particularly the supply of carbohydrate, relief of pain (with opioid), and of hypertension and tachycardia (with propranolol) are important

THE ENVIRONMENT

Significant environmental factors causing adverse

9 www.uwcm.ac.uk/study/medicine/medical_biochem/ porphyria.htm

www.utc.ac.za/depts/liver/porphpts.htm

Trang 7

C A U S E S 8

TABLE 8.2 Drugs that are considered safe for use in acute porphyrias

Acetazolamide

Acetylcysteine

Aciclovir

Adrenaline (epinephrine)

Alfentanil

Allopurinol

Alpha tocopheryl

Aluminium salts

Amantadine

Amethocaine (tetracaine)

Amiloride

Aminoglycosides

Amitriptyline

Amphotericin

Ascorbic acid

Aspirin

Atropine

Azathioprine

Beclomethasone

Beta blockers

Bezafibrate

Bismuth

Bromazepam

Bumetanide

Bupivacaine

Buprenorphine

Buserelin

Calcitonin

Calcium carbonate

Carbimazole

Chloral hydrate

Chloroquine

Chlorothiazide

Chlorpheniramine (chlorphenamine)

Chlorpromazine

Colestyramine

Cisplatin

Clobazam

Clofibrate

Clomifene

Clonazepam

Co-amoxiclav

Co-codamol

Co-dydramol

Codeine phosphate

Colchicine

Colestipol

Corticosteroids

Corticotrophin

Cyclizine

Cyclopenthiazide

Cyclopropane

Dalteparin

Danthron

Desferrioxamine

Dextran Dextromethorphan Dextromoramide Dextropropoxyphene Dextrose

Diamorphine Diazoxide Dicyclomine (dicycloverine) Diflunisal

Digoxin Dihydrocodeine Dimercaprol Dimeticone Diphenhydramine Diphenoxylate Dipyridamole Distigmine Dobutamine Domperidone Dopamine Doxorubicin Droperidol Enalapril Enoxaparin Epinephrine Ethambutol Ether Famciclovir Fenbufen Fenofibrate Fentanyl Flucloxacillin 1

Flucytosine Flumazenil Fluoxetine Fluphenazine Flurbiprofen Fructose FSH Gabapentin Ganciclovir Gemfibrozil Glipizide Glucagon Glucose Glycopyrronium Gonadorelin Goserelin GTN Guanethidine Haloperidol Heparin Hetastarch Hydrochlorothiazide Hydrocortisone

Ibuprofen Immunisations Immunoglobulins Indomethacin Insulin Iron Isoflurane Ispaghula Ketoprofen Ketotifen Lactulose Leuproelin Levothyroxine LHRH Lignocaine 2 (lidocaine) Lisinopril 3

Lithium Lofepramine Loperamide Loratadine Lorazepam Magnesium sulphate Meclozine Mefloquine Melphalan Mequitazine Mesalazine Metformin Methadone Methotrimeprazine (levomepromazine) Methylphenidate

Methylprednisolone Mianserin Midazolam Morphine Naftidrofuryl Nalbuphine Naloxone Naproxen Neostigmine Nitrous oxide Octreotide Omeprazole Oxybuprocaine Oxytocin Pancuronium Paracetamol Paraldehyde Penicillamine Penicillins Pentamidine Pethidine Phentolamine Phytomenadione Pipothiazine

Pirenzepine Prazosin Prednisolone Prilocaine Primaquine Probucol Procainamide Procaine Prochlorperazine Proguanil Promazine Promethazine Propantheline Propofol Propylthiouracil Proxymetacaine Pseudoephedrine Pyridoxine Pyrimethamine Quinidine Quinine Resorcinol Salbutamol Senna Sodium acid phosph Sodium bicarbonate Sodium fusidate Sodium valproate 4

Sorbitol Streptokinase Streptomycin Sucralfate Sulindac Suxamethonium Temazepam Tetracaine Thiamine Thyroxine (levothyroxine) Tiaprofenic acid Tinzaparin Tranexamic acid Triamterene Triazolam Trifluoperazine Trimeprazine Urokinase Vaccines Valaciclovir Valproate 4

Vancomycin Vigabatrin Vitamins Warfarin Zalcitabine Zinc preparations This list is produced jointly by Professor G Elder and Dr M Badminton, the Department of Medical Biochemistry, University Hospital of Wales and the staff of the Welsh Medicines Information Centre (WMIC; fiona.woods@cardiffandvale.wales.nhs.uk) It is based on the best information available at the time of completion Inclusion of a drug does not guarantee that it will be safe in all circumstances.

1 Large intravenous doses may be associated with acute attacks (unproven as causative agent).

2 Intravenous doses should be avoided.

3 Safety under review; contact WMIC.

4 Sodium valproate should be used only where other antiepilepsy drugs are ineffective or inappropriate.

Trang 8

reactions to drugs include simple pollution, e.g.

penicillin in the air of hospitals or in milk (see

below), causing allergy

Drug metabolism may also be increased by

hepatic enzyme induction from insecticide

accumu-lation, e.g dicophane (DDT) and from alcohol and

the tobacco habit, e.g smokers require a higher

dose of theophylline

Antimicrobials used in feeds of animals for

human consumption have given rise to concern in

relation to the spread of resistant bacteria that may

affect man

DRUG INTERACTIONS

(see p 129)

Allergy in response to

drugs

Allergic reactions to drugs are the resultant of

the interaction of drug or metabolite (or a nondrug

element in the formulation) with patient and

disease, and subsequent re-exposure

Lack of previous exposure is not the same as lack

of history of previous exposure, and 'first dose

reactions' are among the most dramatic Exposure

is not necessarily medical, e.g penicillins may occur

in dairy products following treatment of mastitis in

cows (despite laws to prevent this), and penicillin

antibodies are commonly present in those who deny

ever having received the drug Immune responses

to drugs may be harmful (allergy) or harmless; the

fact that antibodies are produced does not mean

a patient will necessarily respond to re-exposure

with clinical manifestations; most of the UK

popula-tion has antibodies to penicillins but, fortunately,

comparatively few react clinically to penicillin

administration

Whilst macromolecules (proteins, peptides,

dex-tran polysaccharides) can act as complete antigens,

most drugs are simple chemicals (mol wt less than

1000) and act as incomplete antigens or haptens,

which become complete antigens in combination

with a body protein

The chief target organs of drug allergy are the

skin, respiratory tract, gastrointestinal tract, blood and blood vessels

Allergic reactions in general may be classified according to four types of hypersensitivity, and drugs can elicit reactions of all types, namely:

Type I reactions: immediate or anaphylactic type.

The drug causes formation of tissue-sensitising IgE antibodies that are fixed to mast cells or leucocytes;

on subsequent administration the allergen (conjugate

of drug or metabolite with tissue protein) reacts with these antibodies, activating but not damaging the cell to which they are fixed and causing release of pharmacologically active substances, e.g histamine, leukotrienes, prostaglandins, platelet activating factor, and causing effects such as urticaria, anaphy-lactic shock and asthma Allergy develops within minutes and lasts 1-2 hours

Type II reactions: antibody-dependent cytotoxic type The drug or metabolite combines with a protein in the body so that the body no longer recognises the protein as self, treats it as a foreign protein and forms antibodies (IgG, IgM) that com-bine with the antigen and activate complement which damages cells, e.g penicillin- or methyldopa-induced haemolytic anaemia

Type III reactions: immune complex-mediated type Antigen and antibody form large complexes and activate complement Small blood vessels are damaged or blocked Leucocytes attracted to the site of reaction engulf the immune complexes and release pharmacologically active substances (including lysosomal enzymes), starting an inflam-matory process These reactions include serum sick-ness, glomerulonephritis, vasculitis and pulmonary disease

Type IV reactions: lymphocyte-mediated type.

Antigen-specific receptors develop on T-lympho-cytes Subsequent administration leads to a local or tissue allergic reaction, e.g contact dermatitis Cross-allergy within a group of drugs is usual, e.g the penicillins When allergy to a particular drug is established, a substitute should be selected from a chemically different group Patients with allergic diseases, e.g eczema, are more likely to develop allergy to drugs

Trang 9

The distinctive features of allergic reactions are

their:10

• Lack of correlation with known pharmacological

properties of the drug

• Lack of linear relation with drug dose (very

small doses may cause very severe effects)

• Rashes, angioedema, serum sickness syndrome,

anaphylaxis or asthma; characteristics of classic

protein allergy

• Requirement of an induction period on primary

exposure, but not on re-exposure

• Disappearance on cessation of administration

and reappearance on re-exposure

• Occurrence in a minority of patients receiving

the drug

• Temporary nature in some cases

• Possible response to desensitisation

PRINCIPAL CLINICAL

MANIFESTATIONS AND TREATMENT

1 Urticarial rashes and angioedema (types I, III).

These are probably the commonest type of drug

allergy Reactions may be generalised, but frequently

are worst in and around the external area of

admin-istration of the drug The eyelids, lips and face are

usually most affected They are usually

accompa-nied by itching Oedema of the larynx is rare but may

be fatal They respond to adrenaline (epinephrine)

(i.m if urgent), ephedrine, H1-receptor antihistamine

and adrenal steroid

2a Nonurticarial rashes (types I, II, IV) These

occur in great variety; frequently they are weeping

exudative lesions It is often difficult to be sure

when a rash is due to a drug Apart from stopping

the drug, treatment is nonspecific; in severe cases

an adrenal steroid should be used Skin

sensitisa-tion to antimicrobials may be very troublesome,

especially amongst those who handle them (see

Drugs and the Skin, Ch 16, for more detail)

2b Diseases of the lymphoid system Infectious

mononucleosis (and lymphoma, leukaemia) is

asso-ciated with an increased incidence (> 40%) of

10 Assem E-S K 1992 In: Davies D M (ed) Textbook of adverse

drug reactions Oxford University Press, London.

A L L E R G Y I N R E S P O N S E T O D R U G S

characteristic maculopapular, sometimes purpuric, rash which is probably allergic, when an amino-penicillin (ampicillin, amoxycillin) is taken; patients may not be allergic to other penicillins Erythromycin may cause a similar reaction

3 Anaphylactic shock (type I) occurs with peni-cillin, anaesthetics (i.v.), iodine-containing radio-contrast media and a huge variety of other drugs

A severe fall in blood pressure occurs, with broncho-constriction, angioedema (including larynx) and sometimes death due to loss of fluid from the intra-vascular compartment Anaphylactic shock usually occurs suddenly, in less than an hour after the drug, but within minutes if it has been given i.v

Treatment is urgent, as follows:

• First, 500 micrograms of adrenaline (epinephrine) injection (0.5 ml of the 1 in 1000 solution) should

be given i.m to raise the blood pressure and to dilate the bronchi (vasoconstriction renders the s.c route less effective) Up to 10% of patients may need a second injection 10-20 min later and subsequent injections may be given until the patient improves Noradrenaline

(norepinephrine) lacks any useful bronchodilator action (p-effect) (see adrenaline, Chapter 23)

• If treatment is delayed and shock has developed, adrenaline 500 micrograms should be given i.v

by slow injection at a rate of 100 micrograms/min (1 ml/min of the Dilute 1 in

10 000 solution over 5 min) with continuous ECG monitoring, stopping when a response has been obtained For greater control and safety, a further

x 10 dilution in dextrose may be preferred (i.e a solution of 1 in 100 000)

• Note that preventive self-management is feasible where susceptibility to anaphylaxis is known, e.g in patients with allergy to bee- or wasp-stings The patient is taught to administer adrenaline i.m from a prefilled syringe (EpiPen Auto-injector, delivering adrenaline 300

micrograms per dose)

• The adrenaline should be accompanied by an H1 -receptor antihistamine [say chlorpheniramine (chlorphenamine) 10-20 mg by slow i.v

injection] and hydrocortisone (100-300 mg i.m

or i.v.) The adrenal steroid may act by reducing vascular permeability and by suppressing

Trang 10

further response to the antigen-antibody

reaction Benefit from an adrenal steroid is not

immediate; it is unlikely to begin for 30 minutes

and takes hours to reach its maximum

• In severe anaphylaxis, hypotension is due to

vasodilation and loss of circulating volume

through leaky capillaries Colloid is more effective

at restoring blood volume than crystalloid and

1-21 of plasma substitute should be infused

rapidly Oxygen and artificial ventilation may be

necessary Advice on the management of

anaphylactic shock may be altered from time to

time; check the UK Resuscitation Council website

(www.resus.org.uk) for current information

Any hospital ward or other place where

ana-phylaxis may be anticipated should have all the

drugs and equipment necessary to deal with it in

one convenient kit, for when they are needed there

is little time to think and none to run about from

place to place (see also Pseudoallergic reactions,

p 146)

4a Pulmonary reactions: asthma (type I) Aspirin

and other nonsteroidal anti-inflammatory drugs

may cause an asthmatic attack Whether this is an

allergic or pseudoallergic reaction or a mixture of

the two is uncertain

4b Other types of pulmonary reaction (type III)

include syndromes resembling acute and chronic lung

infections, pneumonitis, fibrosis and eosinophilia

5 The serum-sickness syndrome (type HI) This

occurs about 1-3 weeks after administration

Treat-ment is by an adrenal steroid, and as above if there

is urticaria

6 Blood disorders 11

6a Thrombocytopenia (type II, but also

pseudo-allergic) may occur after exposure to any of a large

11 Where cells are being destroyed in the periphery and

production is normal, transfusion is useless or nearly so, as

the transfused cells will be destroyed, though in an

emergency even a short cell life (platelets, erythrocytes) may

tip the balance usefully Where the bone marrow is

depressed, transfusion is useful and the transfused cells will

survive normally.

number of drugs, including: gold, quinine, quini-dine, rifampicin, heparin, thionamide derivatives, thiazide diuretics, sulphonamides, oestrogens, indo-methacin Adrenal steroid may help

6b Granulocytopenia (type II, but also pseudo-allergic) sometimes leading to agranulocytosis, is a very serious allergy which may occur with many drugs, e.g clozapine, carbamazepine, carbimazole, chloramphenicol, sulphonamides (including diuretic and hypoglycaemic derivatives), colchicine, gold The value of precautionary leucocyte counts for drugs having special risk remains uncertain.12

Weekly counts may detect presymptomatic granulo-cytopenia from antithyroid drugs but onset can be sudden and an alternative view is to monitor only with drugs having special risk, e.g clozapine The chief clinical manifestation of agranulocytosis is sore throat or mouth ulcers and patients should

be warned to report such events immediately and

to stop taking the drug; but they should not

be frightened into noncompliance with essential therapy Treatment of the agranulocytosis involves both stopping the drug responsible and giving a bactericidal drug, e.g a penicillin, to prevent or treat infection

6c Aplastic anaemia (type II, but not always allergic) Causal agents include chloramphenicol, sulphonamides and derivatives (diuretics, antidiabe-tics), gold, penicillamine, allopurinol, felbamate, phenothiazines and some insecticides, e.g dicophane (DDT) In the case of chloramphenicol, bone marrow depression is a normal pharmacodynamic effect (type

A reaction), although aplastic anaemia may also be due to idiosyncrasy or allergy (type B reaction) Death occurs in about 50% of cases, and treat-ment is as for agranulocytosis, with, obviously, blood transfusion

6d Haemolysis of all kinds is included here for convenience There are three principal categories:

• Allergy (type II) occurs with methyldopa,

levodopa, penicillins, quinine, quinidine,

12 In contrast to the case of a drug causing bone marrow depression as a pharmacodynamic dose-related effect, when blood counts are part of the essential routine monitoring of therapy, e.g cytotoxics.

Ngày đăng: 22/01/2014, 00:20

TỪ KHÓA LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm